AI
Thursday, January 28, 2016 1:42:04 PM
Funny Youtube by Immunotherapy-World-Conf./WashDC re: The Storm.
We were Ready for a Nice Sunny Meeting in Washington.
...AND THEN…
We're right in the middle of The Blizzard of 2016…
BUT WHY LET A LITTLE SNOW SPOIL THE MEETING?
- - - - - -
Thank You to Everyone Who Made It.
- - - - - -
And, See You Next Year in... MIAMI !!
SEE YOU NEXT YEAR!!!
.
.
= = = = = = = = = = = = =
Jan25-27 2016: “Phacilitate's Immunotherapy World Conf.”, WashDC
http://www.immunotherapyforum.com
“After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, immuno-oncology has solidified its status as the most exciting development in cancer treatment for a long time. Now that checkpoint inhibitors have uncloaked cancer cells, drug developers are investigating dozens of immune drug cocktails (everything from CAR-T to antibodies, vaccines and other cellular therapies) to find well-tolerated treatments which could become the first-in-line to fight cancer in patients. We have all heard of the stunning breakthroughs at ASCO'15. BMS’ Opdivo + Yervoy study which lead to a 58% shrinkage of tumors and a PFS superiority of 8.6mos. against monotherapies in patients with melanoma. AstraZeneca’s own PD-L1 (MEDI4736/durvalumab) [see 10-15-15 AZN/PPHM Collab. Expansion: http://tinyurl.com/q79bkam ] and CTLA-4 (Tremelimumab) inhibitor combination, which demonstrated an ORR of 27% in the treatment of NSCLC… On Jan25-27 2016, 750 deal-makers will gather in the Grand Hyatt Hotel to discuss the direction, future and value of cell, gene and immunotherapy portfolios.”
1-24-16 Agenda Update due to storm – everything moved back ~30mins:
http://www.immunotherapyforum.com/files/new_immunotherapy_agenda.pdf
---------
Jan25(Day1): Focus Session1, “Cellular Cancer Immunotherapy: Optimizing Combination Therapy Development Strategy”
3:15pm: Chair's intro, David Lebwohl, NOVARTIS
3:20: Michael Hanna, VACCINOGEN, “The Provocative Issues of Tumor Heterogeneity on Active Specific Immunotherapy...”
3:35: Laura Benjamin, ELI LILLY, “Challenges/Opportunities for Translational Science to Guide Angiogenesis/Combos w/Immunotherapy”
3:50: Taylor Schreiber, HEAT BIOLOGICS, “Dual-Acting Immunotherapy with ComPACT - Vaccination & Co-Stimulation...”
-------
1-25-16 4:05-4:20pm: Jeff T. Hutchins (PEREGRINE'S VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies”
* Analyzing complimentary mechanisms in therapeutics and building solid partnerships
* Utilizing scientifically-driven data to build a product value story
* Demonstrating how a product fits within a treatment in combination(s) and against competitive therapies
-------
4:20pm: Robert Preti, PCT(CALADRIUS), “What Does Commercialization Look Like?”
- - - - - - - - - - - - - - - -From PPHM's 1-20-16 PR: http://tinyurl.com/z65avfw
“In his talk, Dr. Hutchins will discuss strategies for expanding the therapeutic benefit seen with immuno-oncology monotherapies to a broader range of patients using combination treatment approaches. Specifically, he will highlight the strategy of leveraging treatments capable of increasing the number & activity of T-cells in the tumor microenvironment to optimize the therapeutic benefit of immune checkpoint inhibitors such as anti-PD-1/anti-PDL-1 agents. Dr. Hutchins will draw on the company's experience in working with preclinical equivalents of bavituximab, Peregrine's lead investigational phosphatidylserine (PS)-targeting immunotherapy candidate. PS-targeting antibodies have been shown to shift the immunosuppressive functions of immune cells in tumors, resulting in anti-tumor immune responses. Peregrine has generated results from multiple preclinical & clinical-translational studies demonstrating enhanced anti-tumor activity and immune activation when combining equivalent PS-targeting antibodies with conventional chemotherapy or checkpoint inhibitors such as anti-PD-1 agents.”
We were Ready for a Nice Sunny Meeting in Washington.
...AND THEN…
We're right in the middle of The Blizzard of 2016…
BUT WHY LET A LITTLE SNOW SPOIL THE MEETING?
- - - - - -
Thank You to Everyone Who Made It.
- - - - - -
And, See You Next Year in... MIAMI !!
SEE YOU NEXT YEAR!!!
.
.
= = = = = = = = = = = = =
Jan25-27 2016: “Phacilitate's Immunotherapy World Conf.”, WashDC
http://www.immunotherapyforum.com
“After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, immuno-oncology has solidified its status as the most exciting development in cancer treatment for a long time. Now that checkpoint inhibitors have uncloaked cancer cells, drug developers are investigating dozens of immune drug cocktails (everything from CAR-T to antibodies, vaccines and other cellular therapies) to find well-tolerated treatments which could become the first-in-line to fight cancer in patients. We have all heard of the stunning breakthroughs at ASCO'15. BMS’ Opdivo + Yervoy study which lead to a 58% shrinkage of tumors and a PFS superiority of 8.6mos. against monotherapies in patients with melanoma. AstraZeneca’s own PD-L1 (MEDI4736/durvalumab) [see 10-15-15 AZN/PPHM Collab. Expansion: http://tinyurl.com/q79bkam ] and CTLA-4 (Tremelimumab) inhibitor combination, which demonstrated an ORR of 27% in the treatment of NSCLC… On Jan25-27 2016, 750 deal-makers will gather in the Grand Hyatt Hotel to discuss the direction, future and value of cell, gene and immunotherapy portfolios.”
1-24-16 Agenda Update due to storm – everything moved back ~30mins:
http://www.immunotherapyforum.com/files/new_immunotherapy_agenda.pdf
---------
Jan25(Day1): Focus Session1, “Cellular Cancer Immunotherapy: Optimizing Combination Therapy Development Strategy”
3:15pm: Chair's intro, David Lebwohl, NOVARTIS
3:20: Michael Hanna, VACCINOGEN, “The Provocative Issues of Tumor Heterogeneity on Active Specific Immunotherapy...”
3:35: Laura Benjamin, ELI LILLY, “Challenges/Opportunities for Translational Science to Guide Angiogenesis/Combos w/Immunotherapy”
3:50: Taylor Schreiber, HEAT BIOLOGICS, “Dual-Acting Immunotherapy with ComPACT - Vaccination & Co-Stimulation...”
-------
1-25-16 4:05-4:20pm: Jeff T. Hutchins (PEREGRINE'S VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies”
* Analyzing complimentary mechanisms in therapeutics and building solid partnerships
* Utilizing scientifically-driven data to build a product value story
* Demonstrating how a product fits within a treatment in combination(s) and against competitive therapies
-------
4:20pm: Robert Preti, PCT(CALADRIUS), “What Does Commercialization Look Like?”
- - - - - - - - - - - - - - - -From PPHM's 1-20-16 PR: http://tinyurl.com/z65avfw
“In his talk, Dr. Hutchins will discuss strategies for expanding the therapeutic benefit seen with immuno-oncology monotherapies to a broader range of patients using combination treatment approaches. Specifically, he will highlight the strategy of leveraging treatments capable of increasing the number & activity of T-cells in the tumor microenvironment to optimize the therapeutic benefit of immune checkpoint inhibitors such as anti-PD-1/anti-PDL-1 agents. Dr. Hutchins will draw on the company's experience in working with preclinical equivalents of bavituximab, Peregrine's lead investigational phosphatidylserine (PS)-targeting immunotherapy candidate. PS-targeting antibodies have been shown to shift the immunosuppressive functions of immune cells in tumors, resulting in anti-tumor immune responses. Peregrine has generated results from multiple preclinical & clinical-translational studies demonstrating enhanced anti-tumor activity and immune activation when combining equivalent PS-targeting antibodies with conventional chemotherapy or checkpoint inhibitors such as anti-PD-1 agents.”
